Healthcare / Drug Manufacturers - Specialty & GenericNasdaqGS
$18.42
-0.43 (-2.28%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $145.3M · quality 70.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$812M
P/E
11.1x
↓EV/EBITDA
6.5x
↓ROE
12.4%
↑Gross Margin
49.5%
↑Debt/Equity
0.83
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2012–2025 · 13 años de histórico normalizado
Revenue CAGR
+10.2%
FCF CAGR
—
FCF margin
16.5%
FCF / Net income
1.21x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $719.9M · net income $98.1M · FCF $119.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||
| Revenue | $719.9M | $719.9M | $732.0M | $644.4M | $499.0M | $437.8M | $349.8M | $322.4M | $294.7M | $240.2M | $255.2M | $251.5M | $210.5M | $229.7M | $204.3M |
| Net Income | $98.1M | $98.1M | $159.5M | $137.5M | $91.4M | $62.1M | $1.4M | $48.9M | $-5.7M | $3.6M | $9.8M | $-2.8M | $-10.7M | $11.9M | $18.1M |
| EBITDA | $212.3M | $212.3M | $277.3M | $240.3M | $146.2M | $80.1M | $20.0M | $7.0M | $-2.6M | $5.2M | — | — | — | — | — |
| EPS | 2.03 | 2.03 | 3.06 | 2.60 | 1.74 | 1.25 | 0.03 | 0.98 | -0.12 | 0.08 | 0.21 | -0.06 | -0.25 | 0.31 | 0.46 |
| Gross Margin | 49.5% | 49.5% | 51.1% | 54.5% | 49.9% | 45.6% | 41.0% | 40.9% | 36.3% | 37.7% | 40.8% | 30.8% | 24.4% | 37.9% | 44.2% |
| Operating Margin | 19.5% | 19.5% | 28.1% | 30.6% | 21.5% | 16.0% | 3.1% | -0.0% | -2.9% | -0.5% | 6.0% | -2.7% | -8.5% | 7.6% | 12.4% |
| Net Margin | 13.6% | 13.6% | 21.8% | 21.3% | 18.3% | 14.2% | 0.4% | 15.2% | -1.9% | 1.5% | 3.8% | -1.1% | -5.1% | 5.2% | 8.9% |
| Balance Sheet | |||||||||||||||
| Debt/Equity | 0.83 | 0.83 | 0.89 | 0.98 | 0.19 | 0.18 | 0.11 | 0.12 | 0.15 | 0.14 | 0.11 | 0.14 | 0.15 | — | — |
| Current Ratio | 3.85 | 3.85 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||
| Free Cash Flow | $119.0M | $119.0M | $172.3M | $145.3M | $65.1M | $70.5M | $23.4M | $207000.00 | $-8.6M | $4.1M | $17.2M | $-5.3M | — | — | — |
| Returns | |||||||||||||||
| ROE | 12.4% | 12.4% | 21.8% | 21.5% | 17.3% | 13.9% | 0.3% | 12.8% | -1.7% | 1.1% | 3.0% | -0.9% | -3.8% | 4.7% | 7.8% |
| Valuation | |||||||||||||||
| P/E | 11.10 | 11.10 | 11.86 | 24.13 | 16.58 | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 6.47 | 6.47 | 8.61 | 15.83 | 9.98 | — | — | — | — | — | — | — | — | — | — |
| P/B | 1.13 | 1.13 | 2.58 | 5.20 | 2.86 | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||
| Revenue Growth | -1.7% | -1.7% | 13.6% | 29.1% | — | 25.1% | 8.5% | 9.4% | 22.7% | -5.9% | 1.4% | 19.5% | -8.4% | 12.4% | — |
| EPS Growth | -33.7% | -33.7% | 17.7% | 49.4% | — | 4066.7% | -96.9% | 916.7% | -250.0% | -61.9% | 450.0% | 76.0% | -180.6% | -32.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-7.0%
EPS terminal req.
$1.63
Spread vs growth
-26.7%
5Y implied EPS CAGR
-0.5%
EPS terminal req.
$1.98
Spread vs growth
-33.1%
10Y implied EPS CAGR
4.6%
EPS terminal req.
$3.19
Spread vs growth
-38.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-28.4%
Start / end P/E
8.4x → 9.1x
EPS bridge
3.06 → 2.03
Residual
-2.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.